LoneStar Heart raises USD2.4 million in Series C funding
Biomedical firm LoneStar Heart Inc grabbed almost USD2.4 million in a recent Series C funding round. The name of the venture investor was not disclosed. This was according to a report published by Boston business and tech news site Xconomy.
LoneStar Heart Inc is a privately-held biomedical company. At present, the firm is based in Texas and in Laguna Hills, California. The company was founded by James T. Willerson, Eric N. Olson, and Olav B. Bergheim, the firm's web profile said.
The California-based company develops new heart therapies for patients with Advanced Heart Failure (AHF). The firm's goal is to maintain and restore adequate heart function in these patients, Xconomy reported.
The biomedical firm collaborates with the Texas Heart Institute, University of Texas Southern Medical Centers, and a worldwide network of top physicians. Through this collaboration, LoneStar is able to develop a wide portfolio of products for AHF patients. The company uses integrated cardiomechanical and biomolecular technology to develop these products, according to the company's website.